Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- ARCAGY/ GINECO GROUP
- Target Recruit Count
- 250
- Registration Number
- NCT06476184
- Locations
- ๐ฎ๐น
Azienda Ospedaliero-Universitaria Ss.Antonio E Biagio E C.Arrigo Alessandria, Alexandrie, Italy
๐ฎ๐นAzienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico, Bologna, Italy
๐ฎ๐นCareggi University Hospital, Florence, Italy
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
- Conditions
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 528
- Registration Number
- NCT06470243
- Locations
- ๐บ๐ธ
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
๐บ๐ธHighlands Oncology Group - Rogers, Rogers, Arkansas, United States
๐บ๐ธHighlands Oncology Group, Springdale, Arkansas, United States
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06457503
- Locations
- ๐บ๐ธ
University of California, San Francisco, San Francisco, California, United States
A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)
- Conditions
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 278
- Registration Number
- NCT06452277
- Locations
- ๐จ๐ณ
Fujian Cancer Hospital, Fuzhou, Fujian, China
๐จ๐ณHunan Cancer Hospital, Changsha, Hunan, China
๐จ๐ณShanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China
Volrustomig Priming Regimens Exploratory Phase II Platform Study
- Conditions
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT06448754
- Locations
- ๐จ๐ณ
Research Site, Taipei, Taiwan
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 110
- Registration Number
- NCT06449209
- Locations
- ๐บ๐ธ
Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States
๐บ๐ธTallahassee Memorial Physician Partners - Cancer & Hematology Specialists, Tallahassee, Florida, United States
๐บ๐ธCarle Foundation Hospital d/b/a Carle Cancer Center, Urbana, Illinois, United States
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 70
- Registration Number
- NCT06449222
- Locations
- ๐บ๐ธ
Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica, California, United States
๐บ๐ธCarle Foundation Hospital d/b/a Carle Cancer Center, Urbana, Illinois, United States
๐บ๐ธBozeman Health Deaconess Hospital Cancer Center, Bozeman, Montana, United States
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 236
- Registration Number
- NCT06439225
- Locations
- ๐จ๐ฆ
Cross Cancer Institute, Edmonton, Alberta, Canada
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
- Conditions
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Fundaciรณn GECP
- Target Recruit Count
- 129
- Registration Number
- NCT06431633
- Locations
- ๐ช๐ธ
Hospital General de Elche, Elche, Alicante, Spain
๐ช๐ธICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain
๐ช๐ธICO Badalona, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-05-17
- Target Recruit Count
- 240
- Registration Number
- NCT06419673
- Locations
- ๐จ๐ณ
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.